Related Experiment Videos
Biliary beta 2-microglobulin in liver allograft rejection.
D H Adams1, D Burnett, R A Stockley
1Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom.
Hepatology (Baltimore, Md.)
|November 1, 1988
Summary
Measuring beta 2-microglobulin in bile and serum can help diagnose liver transplant rejection. A high bile-to-serum ratio of beta 2-microglobulin indicates acute rejection, aiding in early detection.
Area of Science:
- Transplantation immunology
- Biomarker discovery
- Gastroenterology
Background:
- Beta 2-microglobulin (B2M) is associated with HLA class 1 antigens.
- Liver transplant recipients are susceptible to rejection and complications like cholangitis.
Purpose of the Study:
- To evaluate the utility of beta 2-microglobulin (B2M) levels in bile and serum for diagnosing acute liver transplant rejection.
- To compare B2M levels during rejection with other post-transplant conditions and non-transplant samples.
Main Methods:
- Assayed beta 2-microglobulin (B2M) in bile and serum from 19 liver transplant patients.
- Analyzed B2M levels in relation to rejection, post-transplant cholangitis, stable graft function, and non-transplant controls.
- Calculated bile/serum ratios of B2M and assessed diagnostic performance.
Main Results:
- Serum B2M levels were elevated in all post-transplant patients.
- Biliary B2M levels were significantly higher during acute rejection compared to other groups (p < 0.01).
- A bile/serum B2M ratio of 0.2 demonstrated 96% sensitivity, 87% specificity, and 90% accuracy for diagnosing rejection.
Conclusions:
- Bile/serum ratios of beta 2-microglobulin (B2M) show promise as a diagnostic tool for acute liver allograft rejection.
- Elevated biliary B2M during rejection suggests local release, potentially involving HLA class 1 antigens on biliary epithelium.
- This biomarker may improve the early detection and management of liver transplant rejection.